Company news

ALK-abello A/S news in 2025

ALK-abello A/S's news releases, calls and decks from 2025, newest first.

View company

ALK – Financial calendar for the 2026 financial year

December 22, 2025

Major shareholder announcement

December 19, 2025

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America

December 1, 2025

Nine-month interim report (Q3) 2025 (unaudited)

November 12, 2025

Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025

November 6, 2025

ALK and GenSci partner to expand the AIT market in China

September 17, 2025

Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray

September 8, 2025

ALK expands the Executive Leadership Team to include key commercial regions

September 4, 2025

Six-month interim report (Q2) 2025 (unaudited)

August 21, 2025

Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025

August 14, 2025

ALK upgrades its full-year revenue outlook

August 12, 2025

ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system

July 21, 2025

EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK

July 18, 2025

First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

June 26, 2025

ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025

June 16, 2025

ALK participates at Jefferies Global Healthcare Conference 2025 in New York

June 4, 2025

ITULATEK® approved for treatment of children and adolescents in Canada

May 8, 2025

Calls in 2025

Decks in 2025